Alveolar rhabdomyosarcoma – Diagnostics – Overview of Information and Clinical Research

Alveolar rhabdomyosarcoma is a rare and aggressive form of soft tissue cancer that primarily affects teenagers and young adults, developing from skeletal muscle cells and requiring comprehensive diagnostic testing to guide treatment decisions and enrollment in clinical trials.

Introduction: Who Should Undergo Diagnostics

Alveolar rhabdomyosarcoma, commonly known as ARMS, is a rare type of cancer that develops in skeletal muscle tissue. Because it tends to grow quickly and can spread to other parts of the body, early and accurate diagnosis is essential. Anyone experiencing persistent symptoms should seek medical evaluation, particularly teenagers and young adults, as this age group is most commonly affected by this subtype of rhabdomyosarcoma.^[1]

The main warning sign is usually a lump or swelling that appears in the soft tissue under the skin, most often in the arms, legs, or torso. This lump is typically fast-growing but usually painless, which can make it easy to dismiss as a minor injury or benign growth. However, any lump that grows larger over time or doesn’t go away deserves medical attention. If the tumor is located deeper in the body, symptoms may be less obvious and could include problems related to how the tumor interferes with normal body functions.^[5]

Parents and caregivers should be particularly alert to symptoms in children and adolescents. For instance, if a tumor develops in the head or neck region, it might cause loss of hearing or balance, bulging of the eyes, weakness or numbness in the face, or trouble swallowing. When the tumor affects muscles around the spine, symptoms can include back pain, difficulty walking, or loss of bowel or bladder control. In the area between the genitals and anus, symptoms might include constipation, abdominal pain or bloating, or blood in urine or stool.^[14]

⚠️ Important

While many symptoms of alveolar rhabdomyosarcoma resemble those of less serious conditions, any persistent lump, swelling, or other worrisome symptom in a child or young adult should be evaluated promptly by a healthcare provider. The symptoms can easily be mistaken for minor injuries or infections, but early detection significantly improves treatment outcomes.

It’s important to understand that ARMS is highly aggressive and can present with distant or regional spread at the time of diagnosis in approximately 25 to 30 percent of patients. This means that by the time symptoms appear, the cancer may have already begun to spread through the body via the lymphatic system or bloodstream. For this reason, seeking diagnostic evaluation as soon as symptoms appear is critical.^[7]

Diagnostic Methods for Identifying Alveolar Rhabdomyosarcoma

Diagnosing alveolar rhabdomyosarcoma requires multiple levels of testing because the disease is complex and can be challenging to identify accurately. The diagnostic process typically begins when a patient or their family notices a concerning symptom and seeks medical care. A specialist doctor, often a pediatric oncologist or sarcoma specialist, will conduct a thorough evaluation using a combination of physical examinations, imaging studies, and laboratory tests.^[1]

Physical Examination and Medical History

The diagnostic journey starts with a comprehensive physical examination. The healthcare provider will carefully look at and feel any lump or swelling to assess its size, location, and characteristics. They will also ask detailed questions about when the symptoms started, how they have changed over time, and whether there is any family history of cancer or inherited disorders that might increase the risk of rhabdomyosarcoma. Understanding the patient’s complete medical background helps the doctor determine the most appropriate next steps.^[13]

Imaging Studies

Once a tumor is suspected, several types of imaging tests are used to create detailed pictures of the inside of the body. These images help doctors determine the tumor’s exact location, size, and whether it has spread to other areas. The main imaging techniques include:

X-rays are often used as an initial test to identify whether a tumor is present, particularly in the chest, abdomen, or bones. While X-rays provide basic information, they are usually just the starting point for more detailed imaging.^[16]

Magnetic Resonance Imaging, or MRI, uses powerful magnets and radio waves to create highly detailed images of soft tissues. This test is particularly useful for determining the extent of the tumor and seeing how it relates to surrounding muscles, blood vessels, and other structures. MRI scans help doctors plan the best approach for surgery or other treatments.^[14]

Computed Tomography, or CT scan, uses a series of X-rays taken from different angles and combines them with computer processing to create cross-sectional images. CT scans are excellent for identifying tumors within the abdomen, chest, pelvis, or other sites. They can show the tumor’s size and position with great clarity.^[16]

Positron Emission Tomography, or PET scan, is an imaging test that can find small tumors throughout the body and help determine if treatment is working effectively. PET scans use a small amount of radioactive material to highlight areas where cells are particularly active, which is often the case with cancer cells.^[16]

Ultrasound imaging uses sound waves to create pictures of the inside of the body. It’s sometimes used in addition to CT or MRI to identify the location of a tumor within the abdomen or within a muscle. Ultrasound is non-invasive and doesn’t use radiation.^[16]

Biopsy and Tissue Analysis

The most critical step in diagnosing alveolar rhabdomyosarcoma is the biopsy, which involves removing a small sample of the tumor tissue for microscopic examination. This tissue sample is analyzed by an expert pathologist who specializes in identifying cancer cells. The biopsy is essential because it confirms whether the tumor is indeed rhabdomyosarcoma and determines which specific subtype it is.^[14]

During the pathology analysis, the specialist looks at the structure and appearance of the cells under a microscope. ARMS cells are typically small with little surrounding material, and they often clump together in a way that resembles the air sacs (alveoli) in the lungs, which is how this cancer type got its name. The pathologist also performs specialized tests, including immunostaining, which uses antibodies to detect specific proteins in the cancer cells. For example, staining for proteins called myogenin and MyoD can help distinguish ARMS from other types of rhabdomyosarcoma.^[4]

Another crucial part of the biopsy analysis is looking for specific genetic abnormalities. About 60 percent of all ARMS cases have a genetic change called the PAX3-FOXO1 fusion gene, while another 20 percent have the PAX7-FOXO1 fusion gene. These genetic fusions result from chromosome translocations where parts of different chromosomes swap places. Detecting these fusion genes is important because they help confirm the diagnosis and may influence treatment decisions. The remaining 20 percent of cases don’t have these fusions but are still classified as ARMS based on their appearance under the microscope.^[4]

Additional Specialized Tests

Because alveolar rhabdomyosarcoma can spread to other parts of the body, additional tests are often necessary to check for metastasis. Bone scans and bone marrow biopsies are used to detect whether the cancer has spread to the bones or bone marrow. A bone marrow sample is collected as part of the staging process to ensure that cancer cells haven’t infiltrated this tissue.^[14]

If the tumor is located near the spine or in the muscles around the spine, a lumbar puncture (also called a spinal tap) may be performed. This procedure uses a small needle to take a sample of the fluid that surrounds the spine and brain, checking for any cancer cells that might have spread to the central nervous system.^[14]

Blood and urine tests are also part of the diagnostic workup. While they don’t directly diagnose rhabdomyosarcoma, they provide important information about the patient’s overall health and how well their organs are functioning, which is essential for planning safe and effective treatment.^[16]

Staging and Grouping

Once all the diagnostic tests are completed, doctors assign the tumor a stage number (ranging from 1 to 4) and a group number (also 1 to 4). These numbers define whether the tumor is localized to only one site or has spread to other areas, and how much of the tumor could be removed during biopsy or surgery. Accurate staging and grouping are absolutely critical for planning the most appropriate treatment and predicting outcomes.^[16]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to help patients with alveolar rhabdomyosarcoma. Because this cancer is rare and can be difficult to treat, especially when it has spread or returned after initial treatment, clinical trials offer access to innovative therapies that aren’t yet widely available. However, not every patient can participate in every trial. Specific diagnostic tests are required to determine whether someone qualifies for enrollment.^[8]

Eligibility Screening Tests

Before a patient can join a clinical trial, they must undergo comprehensive eligibility screening. This process uses many of the same diagnostic tests described earlier but applies them to meet very specific criteria set by the trial protocol. The trial’s requirements might include factors such as the patient’s age, the exact location where the tumor started, whether the cancer has spread, and the presence or absence of specific genetic markers like the PAX3-FOXO1 or PAX7-FOXO1 fusion genes.^[7]

Researchers need to confirm the diagnosis with certainty before enrolling patients. This typically requires a fresh biopsy or access to stored tumor tissue that can be re-examined. Advanced molecular testing may be performed to identify genetic characteristics of the tumor. These molecular tests look for specific changes in the cancer’s DNA or the fusion proteins that drive its growth. Understanding these details helps match patients to trials testing treatments that target those specific abnormalities.^[4]

Baseline Health Assessment

Clinical trials also require a thorough assessment of the patient’s baseline health status before treatment begins. This includes blood tests to check organ function, particularly the liver, kidneys, and bone marrow, because many cancer treatments can affect these organs. Heart function may be evaluated with an echocardiogram or electrocardiogram, especially if the trial involves medications known to affect the heart.^[16]

Imaging studies such as CT, MRI, or PET scans are performed to document exactly where the cancer is located and how much disease is present. These baseline images serve as a comparison point to measure whether the treatment is working as the trial progresses. Periodic repeat imaging during the trial helps researchers and doctors see if tumors are shrinking, staying the same size, or growing.^[16]

Risk Stratification

Many clinical trials for rhabdomyosarcoma divide patients into different risk groups based on a combination of factors. These include the stage and group of the cancer, the patient’s age at diagnosis, the subtype (whether it’s embryonal or alveolar), and whether the cancer has spread. Treatment approaches in clinical trials are often tailored to these risk categories. For example, patients with low-risk disease might receive less intensive treatment to reduce side effects, while those with high-risk or metastatic disease might be offered more aggressive or experimental therapies.^[19]

To qualify for a particular risk-stratified trial, patients must undergo all the necessary diagnostic tests to accurately determine their risk category. This ensures that each patient receives the treatment approach most appropriate for their specific situation and that the trial results can be properly interpreted.^[19]

⚠️ Important

Clinical trial participation requires meeting very specific diagnostic criteria, and not all patients will qualify for every trial. However, the comprehensive testing needed for trial enrollment often provides valuable information that can guide treatment decisions even if a patient doesn’t ultimately join a study. Talk with your healthcare team about whether clinical trials might be an option and what additional testing might be required.

Prognosis and Survival Rate

Prognosis

The prognosis for alveolar rhabdomyosarcoma depends on several important factors that doctors consider when estimating outcomes. Children between the ages of 1 and 9 years tend to have better outcomes than those who are younger than 1 year or 10 years and older. The location where the tumor started also matters significantly. Tumors that begin in the area around the eye, certain parts of the head and neck, or organs of the urinary and reproductive system (except the kidney, bladder, and prostate) generally have better prognoses. In contrast, tumors that start in the arms, legs, bladder, prostate, or areas near the membranes surrounding the brain and spinal cord tend to have poorer outcomes.^[21]

The size of the tumor matters as well, with tumors measuring 5 centimeters or less in diameter associated with better prognoses than larger tumors. Whether the cancer has spread at the time of diagnosis is one of the most important factors. Children whose cancer has already spread to distant parts of the body when it is first diagnosed face a much poorer prognosis than those with localized disease. Similarly, if cancer has spread to regional lymph nodes, outcomes are generally worse than when no lymph nodes are involved. If cancer cells are found in the brain and spinal cord, the prognosis is particularly concerning.^[21]

How much of the tumor can be completely removed during surgery is another crucial factor. Children whose tumors can be fully removed usually have better outcomes. The specific type of rhabdomyosarcoma also influences prognosis. Alveolar tumors, particularly those with the PAX3-FOXO1 fusion gene, tend to be more aggressive and have poorer prognoses than embryonal tumors. Alveolar rhabdomyosarcoma grows faster and is more likely to spread to other parts of the body soon after it develops, which makes it more challenging to treat successfully.^[1]^[21]

Survival Rate

Survival rates for alveolar rhabdomyosarcoma vary considerably depending on the combination of prognostic factors described above. For patients classified as low-risk based on factors like stage, tumor location, age, and whether the cancer has spread, the five-year survival rate is approximately 80 to 95 percent. This means that 8 to 9 out of every 10 children with low-risk disease are still alive five years after diagnosis.^[19]

The majority of rhabdomyosarcoma cases fall into the intermediate-risk category, which has a five-year survival rate of 50 to 70 percent. This means that between 5 and 7 out of every 10 children with intermediate-risk disease survive at least five years. However, once the cancer has spread to distant parts of the body (metastasized), which occurs in about 10 to 15 percent of cases at diagnosis and is classified as high-risk, the survival rate drops dramatically to only 20 to 30 percent. This means that only 2 or 3 out of every 10 children with metastatic disease survive five years.^[19]

It’s important to understand that nearly all recurrences of rhabdomyosarcoma occur within three years of the initial diagnosis. Patients who remain cancer-free for more than three years have a much better chance of long-term survival. The long-term outcomes for patients with metastatic rhabdomyosarcoma remain particularly poor despite advances in treatment, which is why ongoing research and clinical trials are so critical for this patient population.^[19]

#1 Clinical Trials Search in Europe